Malignant neoplasm of prostate
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
We previously showed that PTHrP overexpression increases adhesion of the human prostate cancer cell line PC-3 to the ECM molecules collagen type I, fibronectin, and laminin.
|
12686457 |
2003 |
Malignant neoplasm of prostate
|
0.400 |
Biomarker
|
disease |
BEFREE |
These results suggest that the proliferative effects of PTHrP in PC-3 cells are mediated via both autocrine/paracrine and intracrine pathways, and that controlling PTHrP production in prostate cancer may be therapeutically beneficial.
|
11891011 |
2002 |
Malignant neoplasm of prostate
|
0.400 |
Biomarker
|
disease |
BEFREE |
PTHrP is the major pathogenetic factor for hypercalcemia in several malignancies including prostate cancer.
|
12586762 |
2003 |
Malignant neoplasm of prostate
|
0.400 |
Biomarker
|
disease |
CTD_human |
We show that 1,25-dihydroxyvitamin D3 (1,25(OH)2D3) and its non-hypercalcemic analog, EB1089, decrease PTHrP mRNA and cellular protein levels in the androgen-dependent human prostate cancer cell line LNCaP and its androgen-independent derivative, the C4-2 cell line.
|
16243370 |
2006 |
Malignant neoplasm of prostate
|
0.400 |
Biomarker
|
disease |
BEFREE |
Recent studies have shown that a large number of prostate tumors demonstrate the presence of PTHrP despite the fact that prostate cancer is rarely associated with the HHM syndrome.
|
12230264 |
2001 |
Malignant neoplasm of prostate
|
0.400 |
Biomarker
|
disease |
BEFREE |
Thus, continued efforts to elucidate the pathways involved in PTHrP-induced EMT as well as to develop ways to specifically target PTHrP signaling may lead to more effective therapies for prostate cancer.
|
24465715 |
2014 |
Malignant neoplasm of prostate
|
0.400 |
Biomarker
|
disease |
BEFREE |
Because nuclear localization of PTHrP has been associated with an inhibition of apoptosis, the ability of full-length PTHrP to protect prostate cancer cells from apoptotic stimuli was examined.
|
10606251 |
1999 |
Malignant neoplasm of prostate
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Together, these results demonstrate a novel signaling linkage between PTHrP and Wnt signaling pathways that results in downregulation of a Wnt inhibitor allowing for Wnt activity that could contribute the osteoblastic nature of PCa.
|
23752183 |
2014 |
Malignant neoplasm of prostate
|
0.400 |
Biomarker
|
disease |
BEFREE |
Parathyroid hormone-related protein (PTHrP) treatment of osteoblastic cells up-regulated CCL2 and was blocked by a PTHrP antagonist, suggesting that prostate cancer-derived PTHrP plays an important role in elevation of osteoblast-derived CCL2.
|
19176388 |
2009 |
Malignant neoplasm of prostate
|
0.400 |
Biomarker
|
disease |
BEFREE |
Thus, in PTHrP-secreting prostate cancers metastatic to bone, the CaR could initiate a vicious cycle, whereby PTHrP-induced bone resorption releases [Ca(2+)](o) and TGF-beta stored within bone, further increasing PTHrP release and osteolysis.
|
11701443 |
2001 |
Malignant neoplasm of prostate
|
0.400 |
Biomarker
|
disease |
BEFREE |
Taken together, our results showed that prostate cancer-derived PTHrP acts in the bone marrow to potentiate CD11b(+)Gr1(+) cells, which are recruited to tumor tissue where they contribute to tumor angiogenesis and growth.
|
24072746 |
2013 |
Malignant neoplasm of prostate
|
0.400 |
Biomarker
|
disease |
BEFREE |
All three PTHrP isoforms could be detected in normal prostate tissues and prostate cancer with differential RT-PCR.
|
9610565 |
1998 |
Malignant neoplasm of prostate
|
0.400 |
Biomarker
|
disease |
BEFREE |
More recent studies have shown that there is intranuclear localization of PTHrP and that intracrine effects of the peptide are involved in promoting processes that result in tumor progression (nall proliferation, apoptosis, cell attachment and angiogenesis) in prostate cancer.
|
15831076 |
2005 |
Malignant neoplasm of prostate
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
We exploited both concepts by developing a GFP-expressing PCa cell line that expresses PTHrP and studying it in an animal model of malignancy with methods that assess the skeletal progression of this tumor.
|
15389781 |
2005 |
Malignant neoplasm of prostate
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Our main findings are that 1,25D regulates PTHrP levels via multiple pathways in PC-3 and C4-2 (human prostate cancer) cell lines, and regulation is dependent on VDR expression.
|
21664243 |
2011 |
Malignant neoplasm of prostate
|
0.400 |
Biomarker
|
disease |
BEFREE |
Since PTHrP enhances prostate cancer cell growth, this study demonstrates the importance of maintaining adequate levels of 1,25(OH)(2)D(3).
|
11997185 |
2002 |
Malignant neoplasm of prostate
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Six prostate cancer cell lines exhibited constitutive expression of PTHrP and IL-8 that were significantly correlated (r = 0.93; P < 0.01).
|
11280799 |
2001 |
Malignant neoplasm of prostate
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Prostate cancer cell type-specific regulation of the human PTHrP gene via a negative VDRE.
|
12850281 |
2003 |
Malignant neoplasm of prostate
|
0.400 |
Biomarker
|
disease |
BEFREE |
The present experiments examined the ability of PTHrP to influence adhesion of the human prostate cancer cell line PC-3 to several ECM proteins found in normal tissues.
|
12581888 |
2003 |
Malignant neoplasm of prostate
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
We studied the effects of PTHrP expression on prostate cancer behavior directly in a mouse model of human prostate cancer cells that were transfected to express different forms of the polypeptide and then injected intraskeletally.
|
15629138 |
2005 |